AB928 is a dual A2A/A2B adenosine receptor antagonist primarily utilized in the field of medical research, particularly in the development of cancer therapies. It functions by targeting these specific receptors involved in immune regulation, which can help in modulating the tumor microenvironment. This makes it a promising candidate for enhancing the efficacy of immunotherapies by potentially reducing immunosuppression and promoting anti-tumor immune responses. Researchers are exploring its use in combination with other treatments to improve outcomes in various cancer types. Additionally, it shows potential in reducing inflammation and treating other immune-related diseases.